Uzbekistan has introduced a comprehensive regulatory framework governing the conduct of clinical trials for medical devices. The newly approved rules establish clear criteria for when clinical trials are required, define the decision-making process for initiating such trials, and regulate the roles of regulatory authorities, experts, clinical institutions, and applicants. The framework aims to ensure patient safety, scientific validity, and regulatory transparency while facilitating access to innovative medical technologies.

Medical Devices Exempt from Clinical Trials

 

The regulatory framework identifies specific categories of medical devices that may undergo state registration without conducting clinical trials. These include:

• Medical devices classified as low-risk (Class I) under the safety classification system;
• In vitro diagnostic devices that have been prequalified by the World Health Organization or registered with WHO support;
• Medical devices for which clinical trials have already been conducted in Uzbekistan;
• Certain devices recognized based on prior circulation and proven safety and effectiveness, subject to the submission of supporting scientific evidence.

This differentiated approach allows regulators to focus clinical trial requirements on higher-risk devices while accelerating market access for well-established or low-risk products.

Decision-Making Authority and Regulatory Oversight

 

The decision on whether a medical device must undergo clinical trials is taken by an Expert Council operating under the Ministry of Health. This decision is based on a recommendation from the state body responsible for the safety of pharmaceutical and medical products.

Clinical trials are conducted depending on the safety class of the medical device and must involve no fewer than 20 clinical trial subjects, with the possibility of multi-center trials for higher-risk devices. This ensures statistically meaningful results while maintaining proportionality.

Integration with the Medical Device Registration Process

 

The clinical trial framework is closely integrated with the broader system for the state registration of medical devices. After a positive conclusion at the initial expert review stage, laboratory testing and specialized expert examination of the medical device are carried out simultaneously.

An independent expert engaged in the specialized examination evaluates:

• The suitability and accreditation of the clinical base where the trial will be conducted;
• The appropriateness of the clinical trial design;
• The use of modern and advanced methods for assessing safety and effectiveness.

This parallel review model reduces regulatory timelines while preserving rigorous scientific assessment.

Ethical Review and Protection of Trial Subjects

 

A key safeguard within the framework is the mandatory ethical review conducted by a designated ethics committee. Clinical trials may not commence without a positive ethical opinion confirming that the study is ethically justified and that the rights, dignity, and safety of trial participants are adequately protected.

Participation in clinical trials is strictly voluntary and based on informed written consent. Special rules apply when trials involve minors or persons with limited legal capacity, requiring consent from legal representatives. Trial participants retain the right to withdraw at any stage without adverse consequences for their medical care.

Conduct of Clinical Trials and Monitoring

 

Clinical trials must be conducted in approved medical institutions by qualified investigators in accordance with recognized good clinical practice standards. Applicants are responsible for:

• Providing the medical device and related documentation;
• Ensuring insurance coverage for potential harm to trial subjects;
• Monitoring and auditing trial quality and compliance.

Adverse events must be promptly documented and reported. Where serious risks to life or health arise, the competent authority is empowered to suspend or terminate the clinical trial.

Reporting, Final Review, and Market Authorization

 

Upon completion of a clinical trial, a clinical trial report is prepared and submitted for final expert review. The report is assessed for consistency with the approved trial protocol and supporting documentation.

Based on the final expert conclusion, the Expert Council decides whether the medical device may be authorized for use in medical practice or whether registration should be refused. This final decision ensures that only devices meeting established safety and performance standards reach the healthcare system.

Practical Implications for Manufacturers and Importers

 

For manufacturers, importers, and distributors of medical devices, the new framework provides:

• Greater clarity on regulatory expectations;
• Predictable pathways for registration depending on device risk;
• Enhanced alignment with international standards;
• Improved protection against regulatory uncertainty.

At the same time, the framework reinforces public confidence by prioritizing patient safety and evidence-based decision-making.

The introduction of a structured and risk-based system for conducting clinical trials of medical devices represents an important milestone in the development of Uzbekistan’s healthcare regulation. By combining scientific rigor, ethical oversight, and administrative efficiency, the framework supports innovation while ensuring that medical devices used in practice meet high standards of safety and effectiveness